| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1073 | 2021 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 806 | 2022 |
| Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge M Law, T Maruyama, J Lewis, E Giang, AW Tarr, Z Stamataki, ... Nature medicine 14 (1), 25-27, 2008 | 676 | 2008 |
| MAIT cells are activated during human viral infections B Van Wilgenburg, I Scherwitzl, EC Hutchinson, T Leng, A Kurioka, ... Nature communications 7 (1), 11653, 2016 | 473 | 2016 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus D Lavillette, AW Tarr, C Voisset, P Donot, B Bartosch, C Bain, AH Patel, ... Hepatology 41 (2), 265-274, 2005 | 353 | 2005 |
| Standardized EEG interpretation accurately predicts prognosis after cardiac arrest E Westhall, AO Rossetti, AF van Rootselaar, T Wesenberg Kjaer, J Horn, ... Neurology 86 (16), 1482-1490, 2016 | 347 | 2016 |
| Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein A Owsianka, AW Tarr, VS Juttla, D Lavillette, B Bartosch, FL Cosset, ... Journal of virology 79 (17), 11095-11104, 2005 | 340 | 2005 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 338 | 2021 |
| Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding AM Owsianka, JM Timms, AW Tarr, RJP Brown, TP Hickling, A Szwejk, ... Journal of virology 80 (17), 8695-8704, 2006 | 315 | 2006 |
| Human adaptation of Ebola virus during the West African outbreak RA Urbanowicz, CP McClure, A Sakuntabhai, AA Sall, G Kobinger, ... Cell 167 (4), 1079-1087. e5, 2016 | 217 | 2016 |
| Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 AW Tarr, AM Owsianka, JM Timms, PC McClure, RJP Brown, TP Hickling, ... Hepatology 43 (3), 592-601, 2006 | 214 | 2006 |
| Post-discharge surveillance to identify colorectal surgical site infection rates and related costs J Tanner, D Khan, C Aplin, J Ball, M Thomas, J Bankart Journal of Hospital Infection 72 (3), 243-250, 2009 | 201 | 2009 |
| Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants MT Catanese, H Ansuini, R Graziani, T Huby, M Moreau, JK Ball, ... Journal of virology 84 (1), 34-43, 2010 | 192 | 2010 |
| Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein AM Owsianka, AW Tarr, ZY Keck, TK Li, J Witteveldt, R Adair, SKH Foung, ... Journal of General Virology 89 (3), 653-659, 2008 | 178 | 2008 |
| Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus DX Johansson, C Voisset, AW Tarr, M Aung, JK Ball, J Dubuisson, ... Proceedings of the National Academy of Sciences 104 (41), 16269-16274, 2007 | 174 | 2007 |
| Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein M Perotti, N Mancini, RA Diotti, AW Tarr, JK Ball, A Owsianka, R Adair, ... Journal of virology 82 (2), 1047-1052, 2008 | 164 | 2008 |
| Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial PM Bath, P Scutt, CS Anderson, JP Appleton, E Berge, L Cala, M Dixon, ... The Lancet 393 (10175), 1009-1020, 2019 | 159 | 2019 |
| Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection AM Grabowska, F Lechner, P Klenerman, PJ Tighe, S Ryder, JK Ball, ... European journal of immunology 31 (8), 2388-2394, 2001 | 152 | 2001 |
| Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies ZY Keck, TK Li, J Xia, M Gal-Tanamy, O Olson, SH Li, AH Patel, JK Ball, ... Journal of virology 82 (12), 6061-6066, 2008 | 146 | 2008 |
